Infectious triggers and novel therapeutic opportunities in childhood B cell leukaemia.
César CobaledaCarolina Vicente-DueñasIsidro Sanchez-GarciaPublished in: Nature reviews. Immunology (2021)
B cell acute lymphoblastic leukaemia (B-ALL) is the most common form of childhood cancer. Although treatment has advanced remarkably in the past 50 years, it still fails in ~20% of patients. Recent studies revealed that more than 5% of healthy newborns carry preleukaemic clones that originate in utero, but only a small percentage of these carriers will progress to overt B-ALL. The drivers of progression are unclear, but B-ALL incidence seems to be increasing in parallel with the adoption of modern lifestyles. Emerging evidence shows that a major driver for the conversion from the preleukaemic state to the B-ALL state is exposure to immune stressors, such as infection. Here, we discuss our current understanding of the environmental triggers and genetic predispositions that may lead to B-ALL, highlighting lessons from epidemiology, the clinic and animal models, and identifying priority areas for future research.
Keyphrases
- childhood cancer
- end stage renal disease
- newly diagnosed
- ejection fraction
- risk factors
- chronic kidney disease
- young adults
- pregnant women
- primary care
- prognostic factors
- peritoneal dialysis
- patient reported outcomes
- intensive care unit
- single cell
- respiratory failure
- gene expression
- gestational age
- cord blood
- combination therapy
- preterm birth